Patents Examined by Satyanarayana R. Gudibande
  • Patent number: 10408843
    Abstract: The present invention relates to methods for detecting protein S-sulfinylation and S-sulfinylation within thiol groups in proteins, metabolites, or materials.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 10, 2019
    Assignee: The Regents of the University of Michigan
    Inventors: Brent R. Martin, Jaimeen D. Majmudar
  • Patent number: 10376587
    Abstract: Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: August 13, 2019
    Assignee: MannKind Corporation
    Inventors: Marshall Grant, Paul Menkin, Grayson W. Stowell
  • Patent number: 10376466
    Abstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: August 13, 2019
    Assignee: MannKind Corporation
    Inventors: Bryan R. Wilson, Marshall Grant
  • Patent number: 10370426
    Abstract: The present invention relates to a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 6, 2019
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Euh Lim Oh, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • Patent number: 10358471
    Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: July 23, 2019
    Assignees: The Board of Trustees of the University of Arkansas, Ochsner Clinic Foundation, National University Corporation Kagawa university
    Inventors: Robert C. Gensure, Joshua Sakon, Osamu Matsushita, Tulasi Ponnapakkam
  • Patent number: 10350299
    Abstract: The present invention relates to complexes of transcription factor decoys, their delivery to bacteria and their formulation. In particular, the present invention resides in an antibacterial complex comprising a nucleic acid sequence and one or more delivery moieties selected from quaternary amine compounds; bis-aminoalkanes and unsaturated derivatives thereof, wherein the amino component of the aminoalkane is an amino group forming part of a heterocyclic ring; and an antibacterial peptide.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: July 16, 2019
    Assignee: PROCARTA BIOSYSTEMS LTD.
    Inventor: Michael McArthur
  • Patent number: 10335453
    Abstract: The embodiments include methods of improving sexual function in a male with benign prostatic hyperplasia (BPH), using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a male in need thereof.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: July 2, 2019
    Assignee: Nymox Corporation
    Inventor: Paul Averback
  • Patent number: 10335455
    Abstract: An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: July 2, 2019
    Assignee: University of Miyazaki
    Inventors: Kazuo Kitamura, Shinya Ashizuka, Haruhiko Inatsu, Toshihiro Kita
  • Patent number: 10335451
    Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: July 2, 2019
    Assignee: The George Washington University a Congressionally Chartered Not-for-Profit Corporation
    Inventor: Lakhmir Chawla
  • Patent number: 10335450
    Abstract: The present invention generally relates to systems and methods for the transdermal delivery of the heptapeptide ZW1. In some aspects, ZW1 may be contained with a composition comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, liquid crystals, or other configurations. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: July 2, 2019
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 10335369
    Abstract: The invention relates to granules and pharmaceutical compositions comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant obtained by mixing hereof for more than 5 minutes prior to granulation as well as processes for their preparation and use thereof in medicine.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 2, 2019
    Assignee: Novo Nordisk A/S
    Inventor: Thomas Vilhelmsen
  • Patent number: 10330671
    Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including Alzheimer's disease.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: June 25, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ben A. Barres, Beth A. Stevens
  • Patent number: 10322160
    Abstract: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: June 18, 2019
    Assignee: The George Washington University a Congressionally Chartered Not-for-Profit Corporation
    Inventor: Lakhmir Chawla
  • Patent number: 10308683
    Abstract: The invention relates to a new bicyclic lipolantipeptide, representing a new class of lantipeptide, and salts thereof, their preparation from a culture of a Microbacterium arborescens, and their use as antimicrobial agent in the prevention and treatment of infections in humans, animals or plants.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: June 4, 2019
    Assignee: DEINOVE
    Inventors: Josef Aszodi, Denis Carniato, Dominique Le Beller, Guillaume Lesquame, Marie-Helene Quernin
  • Patent number: 10308686
    Abstract: The present invention is directed to a novel class of antimicrobial agents called ?-AApeptides. The current invention provides various categories of ?-AApeptides, for example, linear ?-AApeptides, cyclic ?-AApeptides, and lipidated ?-AApeptides. ?-AApeptides of the current invention are designed to exert antimicrobial activity while being stable and non-toxic. ?-AApeptides also do not appear to lead to the development of microbial resistance in treated microorganisms. Thus, the disclosed ?-AApeptides can be used for the treatment of various medical conditions associated with pathogenic microorganisms.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: June 4, 2019
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jianfeng Cai, Youhong Niu, Haifan Wu, Shruti Padhee
  • Patent number: 10307460
    Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: June 4, 2019
    Assignee: Allegro Pharmaceuticals, LLC
    Inventors: Michael John Mackel, John Park
  • Patent number: 10267799
    Abstract: The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: April 23, 2019
    Assignee: Children's Medical Center Corporation
    Inventor: Randolph Watnick
  • Patent number: 10266652
    Abstract: The invention provides a non-particulate cross-linked poly-?-lysine polymer. The poly-?-lysine and cross linker are linked by amide bonds and may the cross linker has at least two functional groups capable of reacting with an alpha carbon amine of poly-?-lysine. The polymer is suitably insoluble in water and other solvents and is provided in macro form for example a sheet, article or fiber. The macro form polymer is useful in a wide range of applications including wound treatment, as a medical diagnostic comprising a particulate support and a functional material bound or retained by the support and solid phase synthesis of peptides, oligonucleotides, oligosaccharides, immobilisation of species, cell culturing and in chromatographic separation.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: April 23, 2019
    Assignee: SPHERITECH LTD.
    Inventor: Donald A. Wellings
  • Patent number: 10240156
    Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: March 26, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ben A. Barres, Alexander H. Stephan, Beth A. Stevens
  • Patent number: 10239828
    Abstract: A process for preparing guanidino-functional, free radically polymerizable compounds comprises (a) combining (1) an amine compound comprising (i) at least one primary aliphatic amino group and (ii) at least one secondary aliphatic amino group, primary aromatic amino group, or secondary aromatic amino group, and (2) a guanylating agent; (b) allowing or inducing reaction of the amine compound and the guanylating agent to form a guanylated amine compound; (c) combining (1) the guanylated amine compound, and (2) a reactive monomer comprising (i) at least one ethylenically unsaturated group and (ii) at least one group that is reactive with an amino group; and (d) allowing or inducing reaction of the guanylated amine compound and the reactive monomer to form a guanidino-functional, free radically polymerizable compound.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: March 26, 2019
    Assignee: 3M Innovative Properties Company
    Inventors: Jerald K. Rasmussen, George W. Griesgraber, James I. Hembre